Category: pyrrolines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG8-acid(25 mg, 0.042 mmol) in dry CH2CI2 (4 mL) under argon atmosphere. PBD 19 (42 mg, crude)was added straight away and stirring was maintained until the reaction was complete (3hours). The reaction was diluted with CH2CI2 and the organic phase was washed with H20 and brine before being dried over MgSO4, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100%CHCI3 up to 9:1 CHCI3/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG8-acid. The product 20 was isolated in 10% over two steps (6.6 mg). LC/MS 1.16 mm (ES+) m/z (relative intensity) 770.20 ([M + 2H], 40%)., 1334177-86-4

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52532; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1122-10-7,3,4-Dibromo-1H-pyrrole-2,5-dione,as a common compound, the synthetic route is as follows.

General procedure: To a stirred solution of 2,3-dibromomaleimide23 (1.0 mmol) in CH2Cl2 (20ml) Et3N (2.0mmol) and thiol (2.1mmol) were added under argon atmosphere and stirred for 3 h at room temperature. The reaction mixture was evaporated,and the crude product was purified by flash chromatography to give the desired compound.

1122-10-7, 1122-10-7 3,4-Dibromo-1H-pyrrole-2,5-dione 14279, apyrrolines compound, is more and more widely used in various fields.

Reference£º
Article; Csavas, Magdolna; Miskovics, Adrienn; Szcs, Zsolt; Rth, Erzsebet; Nagy, Zsolt L; Bereczki, Ilona; Herczeg, Mihaly; Batta, Gyula; Nemes-Nikodem, Eva; Ostorhazi, Eszter; Rozgonyi, Ferenc; Borbas, Aniko; Herczegh, Pal; Journal of Antibiotics; vol. 68; 9; (2015); p. 579 – 585;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6913-92-4,1-Benzyl-3-pyrroline,as a common compound, the synthetic route is as follows.,6913-92-4

(2) To a solution of triethylamine (4.18 mL) and formic acid (0.384 mL) in N,N-dimethylformamide (20mL) were added dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (205 mg), Compound 3 (1.90 g), Compound 4 (3.98 g), and N,N-dimethylformamide (10 mL), and the mixture was stirred at 95C for 2 hours. To the reaction mixture were added ethyl acetate and water at room temperature, stirred, and then extracted with ethyl acetate. The resultant organic layer was washed with water, dried, and concentrated under reduced pressure. The residue was purified with silica gel column chromatography (hexane:ethyl acetate=100:0-50:50) to give racemic Compound 5 (1.14 g) as a pale yellow viscous material. MS (APCI): m/z 461 [M+H]+

As the paragraph descriping shows that 6913-92-4 is playing an increasingly important role.

Reference£º
Patent; Mitsubishi Tanabe Pharma Corporation; YAMAMOTO, Yasuo; SATO, Atsushi; MOROKUMA, Kenji; SHITAMA, Hiroaki; ADACHI, Takashi; MIYASHIRO, Masahiko; (260 pag.)EP3150578; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55750-49-7,Ethyl 2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carboxylate,as a common compound, the synthetic route is as follows.

55750-49-7, To a solution of 1,5-diaminopentane (0.86 g, 8.5 minol) in water (100 mL) at 0 C was added dropwise a solution of di-tert-butyl dicarbonate (0.46 g, 2.1 minol) in 1,4-dioxane (150 mL), and the mixture stirred at room temperature for 16 h. The mixture was then concentrated by half in vacuo, filtered, and the filtrate extracted with ethyl acetate (3 x). The combined organic layers were then dried over anhydrous magnesium sulfate, filteredand the solution concentrated in vacuo to afford a yellow oil, which was used without further purification. To a solution of the crude oil in saturated aqueous sodium bicarbonate (8 mL) at 0 C was added 45 (248 mg, 1.0 minol), and the mixture stirred at 0 C for 30 minutes. A solution of acetonitrile/water (16 mL, 1:1 v/v) was then added and the mixture stirred at room temperature for 4 h. The mixture was then extracted with dichloromethane (3 x), thecombined organic layers dried over anhydrous magnesium sulfate, filtered and the solutionconcentrated in vacuo. Purification by column chromatography (EtOAc/hexanes, 1:2)afforded the title compound 57 (94 mg, 40%) as a colourless oil. 1H NMR (400 MHz, CDCI3)oe 1.26-1.31 (2H, m, H-3?), 1.42 (9H, s, Boc), 1.45-1.52 (2H, m, H-2?), 1.55-1.63 (2H, m,H-4?), 3.06-3.09 (2H, m, H-i?), 3.50 (2H, t, J = 7.2 Hz, H-5?), 4.50-4.55 (1H, m, NH), 6.67(2H, s, H-3, H-4); 13C NMR (100 MHz, CDCI3) oe 23.9 (CH2, C-3?), 28.2 (CH2, C-4?), 28.4 (3x CH3, Boc), 29.5 (CH2, C-2?), 37.6 (CH2, C-5?), 40.3 (CH2, C-i?), 79.0 (C, Boc), 134.1 (2 xCH, C-3, C-4), 156.0 (C, Boc), 170.8 (2 x C, C-2, C-5); vmax (cm1) 3365, 2939, 1698,1675, 1529, 1412, 1272, 1165, 1117, 832, 695; HRMS-ESI [M+Na] Calcd. forC14H22N2O4Na 304.1472, found 305.1467.

The synthetic route of 55750-49-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SAMMUT, Ivan Andrew; HARRISON, Joanne Clare; HEWITT, Russell James; READ, Morgayn Iona; STANLEY, Nathan John; WOODS, Laura Molly; KUEH, Jui Thiang Brian; JAY-SMITH, Morgan; SMITH, Robin Andrew James; GILES, Gregory; LARSEN, Lesley; RENNISON, David; BRIMBLE, Margaret Anne; LARSEN, David Samuel; (209 pag.)WO2017/95237; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

25021-08-3, 2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-[(N-{(2S)-2-Amino-4-[{(1R)-1-[1-benzyl-4-(2,5-difluorophenyl)-1H-pyrrol-2-yl]-2,2-dimethylpropyl}(glycoloyl)amino]butanoyl}-3-{[(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl) acetyl]amino}-D-alanyl)amino]-3,6,9,12-tetraoxapentadecan-15-oic acid/trifluoroacetic acid (1:1) First, intermediate L91 was coupled with (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid in the presence of HATU and N,N-diisopropylethylamine, and the Boc protective group was then removed using 12.5% strength TFA in DCM. The resulting intermediate was coupled with intermediate C58 in the presence of HATU and N,N-diisopropylethylamine and then converted into the title compound by deprotection with zinc chloride. LC-MS (Method 1): Rt=0.84 min; MS (ESIpos): m/z=984 (M+H)., 25021-08-3

The synthetic route of 25021-08-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; LERCHEN, Hans-Georg; REBSTOCK, Anne-Sophie; CANCHO GRANDE, Yolanda; WITTROCK, Sven; BERNDT, Sandra; GRITZAN, Uwe; FITTING, Jenny; STELTE-LUDWIG, Beatrix; JONES, Patrick; MAHLERT, Christoph; VOTSMEIER, Christian; SCHOeNFELD, Dorian; TRAUTWEIN, Mark; WEBER, Ernst; PAWLOWSKI, Nikolaus; GREVEN, Simone; GLUeCK, Julian Marius; HAMMER, Stefanie; DIETZ, Lisa; MAeRSCH, Stephan; (357 pag.)US2020/138970; (2020); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI.HCI (117 mg, 0.29 mmol) was added to a stirred solution of MAL-dPEG8-acid (360mg, 0.6079 mmol, Stratech Scientific Limited) and amine 120 (608 mg, 0.5526 mmol) inCH2CI2 (15 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 24 hours, at which point analysis by LC/MS showed complete consumption of 120. The reaction mixture was diluted with CH2CI2 and washed successively with sat. NH4CI and sat. NaH 003, dried over Mg504, and concentrated in vacuo to provide thecrude product. Purification by lsoleraTM (4-16% MeOH in CH2CI2) gave amide 121 as a white solid (77 mg, 79% purity (UV integration 223 nm) 8.8% crude yield; 107 mg, 88% purity, 12% crude yield; 224 mg, 86% purity, 25% crude yield)., 1334177-86-4

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip Wilson; GREGSON, Stephen John; (207 pag.)WO2018/192944; (2018); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1122-10-7, 3,4-Dibromo-1H-pyrrole-2,5-dione is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a stirred solution of 2,3-dibromomaleimide23 (1.0 mmol) in CH2Cl2 (20ml) Et3N (2.0mmol) and thiol (2.1mmol) were added under argon atmosphere and stirred for 3 h at room temperature. The reaction mixture was evaporated,and the crude product was purified by flash chromatography to give the desired compound., 1122-10-7

The synthetic route of 1122-10-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Csavas, Magdolna; Miskovics, Adrienn; Szcs, Zsolt; Rth, Erzsebet; Nagy, Zsolt L; Bereczki, Ilona; Herczeg, Mihaly; Batta, Gyula; Nemes-Nikodem, Eva; Ostorhazi, Eszter; Rozgonyi, Ferenc; Borbas, Aniko; Herczegh, Pal; Journal of Antibiotics; vol. 68; 9; (2015); p. 579 – 585;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(d) 1-(3-(2, 5-dioxo-2 , 5-dihydro- 1H-pyrrol- 1-yl)propanamido)-N-((S)- 1-(((S)- 1-((4-((S)-7- methoxy-8-((5-(((S)- 7-methoxy-2-(4-(4-methylpiperazin- 1-yl)phenyl)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-8-yl) oxy)pentyl) oxy)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-2-yl)phenyl)amino) – 1-oxopropan-2-yl)amino)-3-methyl- 1- oxobutan-2-yl)-3, 6,9, 12,15, 18,21, 24-octaoxaheptacosan-2 7-amide (91)Piperidine (0.2 mL) was added to a solution of 90 (77 mg, 63.4 pmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over Mg504, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 mm (ES+) m/z(relative intensity) 784.25 (([M+ 2H]2j/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgSO4), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCI3/MeOH) gave 91 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, ODd3) O 8.73 (5, 1H), 7.88 (dd, J= 7.6, 3.9 Hz, 2H), 7.75 (d, J= 8.6 Hz, 2H), 7.52 (d, J= 2.0 Hz, 2H), 7.44 (5, 1H), 7.40-7.28 (m, 4H), 6.91 (d, J= 8.8 Hz, 2H), 6.81 (5, 2H), 6.69 (5, 2H),6.48 (5, 1 H), 4.72 -4.63 (m, 1 H), 4.46 -4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (5, 4H), 3.84 (dd, J = 17.2, 10.1 Hz, 4H), 3.72 -3.46 (m, 30H), 3.44 -3.32 (m, 4H), 3.30-3.20 (m, 4H), 2.75-2.63 (m, 1H), 2.59 (5, 4H), 2.55-2.43 (m, 3H), 2.37 (5, 3H), 2.29 (dd, J= 12.7, 6.7 Hz, 1H), 2.03-1.89 (m, 4H), 1.72 (d, J= 22.7 Hz, 8H), 1.46 (d, J= 7.2 Hz, 3H), 1.01 (dd, J = 11.5, 6.9 Hz, 6H). MS (ES) m/z (relative intensity) 784.25 (([M+ 2H]2)/2, 100).

1334177-86-4, As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; VAN BERKEL, Patricius Henrikus Cornelis; HOWARD, Philip Wilson; WILLIAMS, David G; WO2015/159076; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

766-36-9, 3-Ethyl-4-methyl-2,5-dihydro-1H-pyrrol-2-one is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,766-36-9

Compound 4 (0.30 g, 0.98 mmol) and 3-ethyl-4-methyl-1,5-dihydro-2H-pyrrol-2-one (0.14 g, 1.12 mmol) were dissolved in a mixture of 4 M KOH (12 mL) and methanol (7 mL) resulting in a yellow mixture. The reaction mixture was heated at reflux under N2 atmosphere for 24 h. After 24 h, the solution was cooled to rt then acidified with HCl (conc.) until red on pH paper, resulting in a yellow precipitate (0.27 g, 0.94 mmol, 96percent). Mp 345?351 ¡ãC. 1H NMR (400 MHz, DMSO, 30 ¡ãC) delta (ppm) 12.33 (s, 1H), 6.57(s, 1H), 2.59 (s, 3H), 2.31 (q, J=7.87 Hz, 2H), 2.13 (s, 3H), 1.04 (t, J=7.48 Hz, 3H); 13C NMR (100 MHz, DMSO, 30 ¡ãC): delta (ppm) 168.2, 162.7, 157.0, 141.9, 141.2, 137.6, 133.3, 128.2, 123.7, 116.1, 96.2, 16.6, 13.4, 11.4, 9.81; IR (ATR) (cm?1): 3330 (w), 3019 (w), 1732 (s), 1657 (s), 1525 (w), 1470 (m), 1292 (s), 1275 (s), 1185 (m), 1107 (m), 775 (m), 704 (m); HR-MS (ESI+) C15H14N2O4 calcd: 286.0954 amu; found 286.0950 amu.

As the paragraph descriping shows that 766-36-9 is playing an increasingly important role.

Reference£º
Article; Jarvis, Tia; Saint-Louis, Carl Jacky; Fisch, Alexander R.; Barnes, Korry L.; Dean, Dolan; Flores, Luis A.; Hunt, Thomas F.; Munro, Lyndsay; Simmons, Tyler J.; Catalano, Vincent J.; Zhu, Lei; Schrock, Alan K.; Huggins, Michael T.; Tetrahedron; vol. 74; 14; (2018); p. 1698 – 1704;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25021-08-3,2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

200 mg (0.594 mmol) of tert-butyl (14-amino-3,6,9,12-tetraoxatetradec-1-yl)carbamate, 111 mg (0.713 mmol) of (2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid and 410 mul (2.4 mmol) of N,N-diisopropylethylamine were dissolved in 6 ml of dimethylformamide, and 339 mg (0.892 mmol) of HATU were added. The reaction mixture was stirred at RT for 1 h and purified directly by preparative RP-HPLC (column: Reprosil 250¡Á30; 10mu, flow rate: 50 ml/min, MeCN/water, 0.1% TFA). The solvents were evaporated under reduced pressure and the residue was dried under high vacuum. This gave 130 mg (43% of theory) of tert-butyl [17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-16-oxo-3,6,9,12-tetraoxa-15-azaheptadec-1-yl]carbamate. LC-MS (Method 1): Rt=0.71 min; MS (ESIpos): m/z=474 (M+H)+.

25021-08-3, 25021-08-3 2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetic acid 319935, apyrrolines compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER PHARMA AKTIENGESELLSCHAFT; LERCHEN, Hans-Georg; REBSTOCK, Anne-Sophie; MARX, Leo; JOHANNES, Sarah Anna Liesa; STELTE-LUDWIG, Beatrix; DIETZ, Lisa; TERJUNG, Carsten; MAHLERT, Christoph; GREVEN, Simone; SOMMER, Anette; BERNDT, Sandra; (481 pag.)US2019/77752; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem